HC Wainwright Forecasts BiomX’s Q1 Earnings (NYSEMKT:PHGE)

BiomX Inc. (NYSEMKT:PHGE) – Investment analysts at HC Wainwright issued their Q1 2025 earnings estimates for shares of BiomX in a note issued to investors on Tuesday, April 1st. HC Wainwright analyst J. Pantginis forecasts that the company will earn ($0.42) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $21.00 price target on the stock. The consensus estimate for BiomX’s current full-year earnings is ($0.44) per share. HC Wainwright also issued estimates for BiomX’s Q2 2025 earnings at ($0.46) EPS, Q3 2025 earnings at ($0.49) EPS, Q4 2025 earnings at ($0.53) EPS, FY2025 earnings at ($1.90) EPS, FY2026 earnings at ($1.86) EPS, FY2027 earnings at ($2.08) EPS and FY2028 earnings at ($1.84) EPS.

BiomX Price Performance

BiomX has a 52 week low of $0.48 and a 52 week high of $4.99. The company has a current ratio of 2.84, a quick ratio of 2.84 and a debt-to-equity ratio of 0.51. The business has a 50 day moving average of $0.71 and a 200 day moving average of $0.75. The stock has a market capitalization of $13.89 million, a P/E ratio of -0.76 and a beta of 1.38.

Hedge Funds Weigh In On BiomX

Hedge funds have recently bought and sold shares of the company. Alyeska Investment Group L.P. purchased a new position in shares of BiomX in the 4th quarter worth approximately $632,000. JPMorgan Chase & Co. purchased a new stake in shares of BiomX during the fourth quarter valued at approximately $314,000. Finally, Allostery Investments LP bought a new stake in BiomX during the fourth quarter worth $470,000. 40.57% of the stock is owned by hedge funds and other institutional investors.

About BiomX

BiomX Inc, a clinical-stage biopharmaceutical company, develops products using natural and engineered phage technologies designed to target and kill specific harmful bacteria associated with chronic disease. It is developing BX211, a phage therapy, which is in phase 2 clinical study for the treatment of diabetic foot osteomyelitis.